BR0309113A - Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas - Google Patents

Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas

Info

Publication number
BR0309113A
BR0309113A BR0309113-9A BR0309113A BR0309113A BR 0309113 A BR0309113 A BR 0309113A BR 0309113 A BR0309113 A BR 0309113A BR 0309113 A BR0309113 A BR 0309113A
Authority
BR
Brazil
Prior art keywords
carbidopa
controlled release
preparation
pharmaceutical compositions
processes
Prior art date
Application number
BR0309113-9A
Other languages
English (en)
Inventor
Mona Gogia
Rajeev Shankar Mathur
Sanjeev Sethi
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0309113A publication Critical patent/BR0309113A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

"COMPOSIçãO FARMACêUTICAS DE LIBERAçãO CONTROLADA DE CARBIDOPA E LEVODOPA E PROCESSO PARA A PREPARAçãO DAS MESMAS". A presente invenção refere-se a composições farmacêuticas de liberação controlada de carbidopa e levodopa que incluem uma combinação de éteres de celulose de pesos moleculares diferentes e em particular o éter de hidroxipropil celulose.
BR0309113-9A 2002-04-11 2003-04-11 Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas BR0309113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN447DE2002 2002-04-11
PCT/IB2003/001361 WO2003084514A1 (en) 2002-04-11 2003-04-11 Controlled release pharmaceutical compositions of carbidopa and levodopa

Publications (1)

Publication Number Publication Date
BR0309113A true BR0309113A (pt) 2005-02-01

Family

ID=28687123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309113-9A BR0309113A (pt) 2002-04-11 2003-04-11 Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas

Country Status (7)

Country Link
US (1) US20060159751A1 (pt)
EP (1) EP1496868A1 (pt)
AU (1) AU2003214551A1 (pt)
BR (1) BR0309113A (pt)
EA (1) EA200401334A1 (pt)
MX (1) MXPA04009906A (pt)
WO (1) WO2003084514A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123021A1 (ja) 2006-04-12 2007-11-01 Nippon Soda Co., Ltd. 徐放性錠剤の製造方法
AU2007241809A1 (en) * 2006-04-20 2007-11-01 Itoham Foods Inc. Pharmaceutical composition for conformational disease
EP2432454B1 (en) 2009-05-19 2017-03-01 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
BR112016021034A8 (pt) 2014-03-13 2021-06-29 Neuroderm Ltd composição farmacêutica, uso da mesma e kit
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US20220071909A1 (en) * 2020-08-26 2022-03-10 Rubicon Research Private Limited Modified release formulations of levodopa
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
AU6589200A (en) * 1999-09-10 2001-04-17 Ranbaxy Laboratories Limited Extended release formulation of etodolac
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa

Also Published As

Publication number Publication date
WO2003084514A1 (en) 2003-10-16
EP1496868A1 (en) 2005-01-19
MXPA04009906A (es) 2004-12-13
US20060159751A1 (en) 2006-07-20
EA200401334A1 (ru) 2005-04-28
AU2003214551A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BRPI0515316A (pt) compostos de imidazoquinolina
BRPI0719488A2 (pt) "composição, processo de preparação da composição, uso de uma composição e uso cosmético de uma composição"
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
BRPI0718615B8 (pt) processo para produzir um material elástico a partir de tropoelastina e material elástico
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
BR0309113A (pt) Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
BRPI0311516A8 (pt) Composição de xampu de condicionamento e seu método de preparo
BRPI0717970B8 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
BRPI0516363A (pt) composição para cuidado dos cabelos e processo para preparação de uma composição
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
BR0210139A (pt) Composições farmacêuticas
BR0317420A (pt) Luva tratada com camomila/aloe vera
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
ECSP034442A (es) Mezclas de polisacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BRPI0408848A (pt) formulações orais de cladribine
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
WO2007016201A3 (en) FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]